Inclusion Criteria:

1. Male or female, ≥18 years of age

2. For the Pharmacokinetic Drug Interaction Study: Histologically or cytologically
confirmed advanced solid tumors that are refractory to all standard of care therapy
or for whom no standard therapy is available, or for whom other standard therapies
the patient has denied. For the Pharmacodynamic Study: Histologically or
cytologically confirmed metastatic/advanced ovarian carcinoma or metastatic/advanced
KRAS mutant colorectal cancer or metastatic/advanced HNSCC that are refractory to all
standard therapies therapy or for whom no standard therapy is available, or for whom
other standard therapies the patient has denied.

3. At least one measurable tumor as defined by RECIST

4. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of
all prior systemic anticancer therapy

5. ECOG of 0 to 2

6. Organ &marrow function as defined in the protocol.

7. No evidence of preexisting uncontrolled hypertension as documented by two baseline
blood pressure readings taken at least 1 hour apart

8. Clinically euthyroid

9. Normal range cardiac function

10. For female patients of child-bearing potential, a negative serum pregnancy test at
Screening.

11. Current use of an acceptable form of double-barrier birth control

12. Have provided written informed consent

Exclusion Criteria:

1. Known brain or other central nervous system metastases metastases that are not stable
for 3 months or longer

2. Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other
gastrointestinal conditions with increased risk of perforation.

3. Major surgery, radiotherapy, chemotherapy, or cytokine therapy within 28 days of
Study Day 0;

4. History of intratumoral bleeding or evidence of bleeding diathesis or coagulopathy

5. Female patients who are pregnant, planning a pregnancy, or who are breastfeeding

6. Known allergy or hypersensitivity to JI-101 or everolimus or any component of the
investigational products

7. Use of an investigational drug/device/biologic within 28 days of Study Day 0

8. Current drug or alcohol abuse or history of drug or alcohol abuse within the past two
years

9. Known history of or serologic positivity for the Hepatitis B Virus (HBV), or the
Hepatitis C Virus (HCV), or for the human immunodeficiency virus (HIV)

10. History of cardiac abnormalities

11. Gastrointestinal (GI) abnormalities

12. Use of concomitant medications that prolong the QT/QTc interval within 14 days prior
to Study Day 0

13. History of cerebrovascular accident including transient ischemic attack within the
past 6 months

14. History of pulmonary embolism or deep vein thrombosis within the past 6 months

15. History of significant retinopathy or any progressive eye disease that could lead to
severe loss of visual acuity or visual field loss during the study period

16. Treatment with heparin or heparin analogs

17. Inability or unwillingness to meet the requirements of the study

18. Other current active malignancy or history of malignancy within the past five years,
except for cervical carcinoma in situ, basal cell carcinoma that has been surgically
removed, or prostate cancer that is being managed with watchful waiting.

19. Any clinically significant abnormal finding at screening that the investigator
judges would interfere with study participation